Please use this identifier to cite or link to this item:
|Title:||High dose rate brachytherapy boost for prostate cancer: Biochemical control and the impact of transurethral resection of the prostate and hydrogel spacer insertion on toxicity outcomes.|
|Authors:||Chao, Michael;Bolton, Damien M;Lim Joon, Daryl;Chan, Yee;Lawrentschuk, Nathan;Ho, Huong;Spencer, Sandra;Wasiak, Jason;Guerrieri, Mario;Ow, Darren;Troy, Andrew J;Pham, Trung;Sengupta, Shomik;Tan, Alwin;McMillan, Kevin;Koufogiannis, George;Foroudi, Farshad;Ng, Michael;Khoo, Vincent|
|Affiliation:||The Valley Private Hospital, Melbourne, Victoria, Australia|
Genesis Cancer Care Victoria, Ringwood, Australia
Austin Health, Heidelberg, Victoria, Australia
University of Melbourne, Melbourne, Victoria, Australia
Monash University, Melbourne, Victoria, Australia
Royal Marsden Hospital, London, UK..
Ringwood Private Hospital, Melbourne, Victoria, Australia
The Box Hill Hospital, Melbourne, Victoria, Australia
The Bays Hospital, Mornington, Victoria, Australia
|Citation:||Journal of medical imaging and radiation oncology 2019; online first: 25 March|
|Abstract:||To examine the long-term outcomes of high dose rate brachytherapy boost (HDR-BT) combined with external beam radiotherapy (EBRT) for intermediate and high-risk prostate cancer patients. Data from 95 patients who underwent combined EBRT (50.4 Gy) and HDR-BT to the prostate between 2010 and 2017 were retrospectively analysed. Biochemical progression free survival (bPFS), local recurrence free survival (LRFS), metastatic free survival (MFS) and overall survival (OS) were estimated using Kaplan-Meier method. Regression analysis was conducted to identify important predictors of outcomes. A total of 24 patients received an initial HDR-BT dose of 18 Gy in three fractions, with the remaining 71 patients receiving 16 Gy in two fractions as per departmental protocol changes. Most patients (88%) received androgen deprivation therapy. A transurethral resection of the prostate (TURP) was performed in 14 patients and hydrogel spacers (HS) were used in 30 patients. Median follow-up was 58 months. The 5-year bPFS, LRFS, MFS and OS were 92%, 100%, 92% and 88%. Univariate regression revealed no statistical association between patient characteristics and time to relapse (all P > 0.1). Late > grade 2 genitourinary (GU) toxicity was 6.3%. The use of HS or prior TURP had no impact on late GU toxicity. Late Grade 1 gastrointestinal (GI) toxicity was 5.3%. The combined HDR-BT with EBRT resulted in excellent bPFS. The cumulative risk of late GU and GI toxicity was low and can be further improved with preventative strategies such as a pre-emptive TURP and/or HS insertion.|
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.